Literature DB >> 23572272

Development of acute kidney injury during continuous infusion of vancomycin in septic patients.

S Cianferoni1, A Devigili, E Ocampos-Martinez, L Penaccini, S Scolletta, A Abdelhadii, D De Backer, M Beumier, F Jacobs, J-L Vincent, F S Taccone.   

Abstract

PURPOSE: Few data are available on the occurrence of renal failure during continuous infusion of vancomycin in critically ill patients.
METHODS: We reviewed the data of all patients admitted to the intensive care unit (ICU) between January 2008 and December 2009 in whom vancomycin was given as a continuous infusion for more than 48 h in the absence of renal replacement therapy. We collected data on the doses of vancomycin and blood concentrations during therapy. Acute kidney injury (AKI) was defined as a daily urine output <0.5 ml/kg/h and/or an increase in the serum creatinine of ≥0.3 mg/dl from baseline levels during vancomycin therapy or within 72 h after its discontinuation. Multivariable logistic regression analysis was performed to identify predictors of AKI.
RESULTS: Of 207 patients who met the inclusion criteria, 50 (24 %) developed AKI. These patients were more severely ill, had lower creatinine clearance at admission, were more frequently exposed to other nephrotoxic agents, had a longer duration of therapy, and had higher concentrations of vancomycin during the first 3 days of treatment (C(mean)). The C(mean) was independently associated with early AKI (within 48 h from the onset of therapy) and the duration of vancomycin administration with late AKI.
CONCLUSIONS: AKI occurred in almost 25 % of critically ill patients treated with a continuous infusion of vancomycin. Vancomycin concentrations and duration of therapy were the strongest variables associated with the development of early and late AKI during therapy, respectively.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572272     DOI: 10.1007/s15010-013-0460-9

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  45 in total

Review 1.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

2.  Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.

Authors:  Lindsey Pritchard; Catherine Baker; James Leggett; Paul Sehdev; Allen Brown; K Bruce Bayley
Journal:  Am J Med       Date:  2010-12       Impact factor: 4.965

Review 3.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

4.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

5.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

Authors:  Richard G Wunderink; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Mark J Kunkel; Alice Baruch; William T McGee; Arlene Reisman; Jean Chastre
Journal:  Clin Infect Dis       Date:  2012-01-12       Impact factor: 9.079

6.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

7.  Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.

Authors:  Doris Hutschala; Christian Kinstner; Keso Skhirdladze; Florian Thalhammer; Markus Müller; Edda Tschernko
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

8.  Mild nephrotoxicity associated with vancomycin use.

Authors:  N J Downs; R E Neihart; J M Dolezal; G R Hodges
Journal:  Arch Intern Med       Date:  1989-08

9.  Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia.

Authors:  A E Zimmermann; B G Katona; K I Plaisance
Journal:  Pharmacotherapy       Date:  1995 Jan-Feb       Impact factor: 4.705

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  5 in total

Review 1.  THE ENDOTHELIUM IN SEPSIS.

Authors:  Can Ince; Philip R Mayeux; Trung Nguyen; Hernando Gomez; John A Kellum; Gustavo A Ospina-Tascón; Glenn Hernandez; Patrick Murray; Daniel De Backer
Journal:  Shock       Date:  2016-03       Impact factor: 3.454

2.  New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.

Authors:  Stefano Cristallini; Maya Hites; Hakim Kabtouri; Jason A Roberts; Marjorie Beumier; Frederic Cotton; Jeffrey Lipman; Frédérique Jacobs; Jean-Louis Vincent; Jacques Creteur; Fabio Silvio Taccone
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction.

Authors:  Savino Spadaro; Angela Berselli; Alberto Fogagnolo; Maurizia Capuzzo; Riccardo Ragazzi; Elisabetta Marangoni; Sara Bertacchini; Carlo Alberto Volta
Journal:  BMC Anesthesiol       Date:  2015-06-27       Impact factor: 2.217

4.  Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study.

Authors:  Katia Donadello; Jason A Roberts; Stefano Cristallini; Marjorie Beumier; Kiran Shekar; Frédérique Jacobs; Asmae Belhaj; Jean-Louis Vincent; Daniel de Backer; Fabio Silvio Taccone
Journal:  Crit Care       Date:  2014-11-22       Impact factor: 9.097

Review 5.  Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.

Authors:  Katie E Barber; Allison M Bell; Kayla R Stover; Jamie L Wagner
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.